Semaglutide - ALZFORUM
Semaglutide is a synthetic, long-acting analog of glucagon-like peptide-1, used to treat diabetes. Ozempic TM is a once-per-week injection formulation, while Rybelsus TM is is a daily pill. Rybelsus TM was approved by the U.S. FDA in September 2019 as the first GLP-1 analog that does not need to be injected.
Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction ...
Could GLP-1 Receptor Agonists Like Semaglutide Treat Addiction, Alzheimer Disease, and Other Conditions?. JAMA. 2024 May 14;331(18):1519-1521. PubMed. Recommends. Please login to recommend the paper. Comments. No Available Comments. Make a Comment. To make a comment you must login or register.
Semaglutide Attenuates Anxious and Depressive-Like Behaviors …
Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis. J Neuroimmune Pharmacol . 2024 Jul 23;19(1):36.
Semaglutide as a possible therapy for healthy aging: Targeting the ...
Semaglutide as a possible therapy for healthy aging: Targeting the hallmarks of aging. Ageing Res Rev. 2024 Dec;102:102582. Epub 2024 Nov 14 PubMed. Recommends. Please login to recommend the paper. Comments. No Available Comments. Make a Comment. To make a comment you must login or register.
Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its ...
Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Apr 15;1221:123688. Epub 2023 Mar 22 PubMed. Recommends. Please login to recommend the paper. Comments. No Available Comments. Make a Comment
Liraglutide - ALZFORUM
Sep 23, 2024 · Diabetes, high blood sugar, and insulin resistance are all associated with dementia. In Alzheimer’s disease, there is evidence for insulin resistance in the brain. Thus, there has been much interest in testing liraglutide and other GLP-1 analogs, such as exendin-4, semaglutide, and lixisenatide, as potential therapeutics for AD.
The Discovery and Development of Liraglutide and Semaglutide
The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol (Lausanne). 2019;10:155. Epub 2019 Apr 12 PubMed. Recommends. Please login to recommend the paper. Comments. No Available Comments. Make a Comment. To make a …
Dapagliflozin - ALZFORUM
Mar 9, 2020 · Type 2 diabetes is a risk factor for developing dementia, and people with Alzheimer’s disease display signs of insulin resistance in the brain. These findings have spurred testing of multiple classes of diabetes drug for the treatment or prevention of AD (for example, see nasal insulin, pioglitazone, metformin, liraglutide and semaglutide).
Therapeutics - ALZFORUM
Nov 25, 2015 · Find a Therapeutic By Name Go NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-552 ABBV-916 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 ABvac40 ACD856 Acetyl-l-carnitine HCI ACI-24.060 ACI-3024 ACI-35 ACI-7104.056 Acitretin ACP-204 ADEL-Y01 Aduhelm AF 102B Affitope AD02 AGB101 AIT-101 AKST4290 AL002 AL003 AL044 AL101 ALIA-1758 Allopregnanolone ALPHA ...
Bile Acid: An Elixir of Youth? | ALZFORUM
Jan 8, 2025 · Intriguingly, LCA also increased glucagon-like peptide 1 levels in mice. Some scientists have suggested that GLP-1 receptor agonists such as semaglutide might slow aging (e.g., Ortiz and de Freitas, 2024). Seeing GLP-1 appear in this context adds support to such claims, said Marc Tatar of Brown University in Providence, Rhode Island, who was ...